Citations

Clear

479 citation(s) found for "Tobias, JS".

Predictors and Outcomes of Excellent Recanalization Versus Successful Recanalization After Thrombectomy in Proximal and Distal Medium Vessel Occlusion Strokes: A Multinational Study
Yedavalli, Vivek , Salim, Hamza , Adeeb, Nimer , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane , Ghozy, Sherief, Heit, Jeremy J. , Regenhardt, Robert W. , Puri, Ajit S., Dyzmann, Christian , Barreau, Xavier , Renieri, Leonardo, Filipe, João Pedro , Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Stracke, Christian Paul , Shaikh, Hamza , Liebeskind, David S., Alexandre, Andrea , Tancredi, Illario , Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Investigators, the MAD MT, Liebeskind, David S. , Salim, Hamza , Liebeskind, David S. , Heit, Jeremy J , Altschul, David J , Gonzalez, Nestor R , Regenhardt, Robert W , Yedavalli, Vivek S , Henninger, Nils , Alexandre, Andrea M , Varela, Ricardo , Musmar, Basel , Naamani, Kareem El , Kühn, Anna Luisa , Ghozy, Sherief , Scarcia, Luca , Tan, Benjamin Yong‐Qiang , Cancelliere, Nicole M , Bernstock, Joshua D. , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil A , Essibayi, Muhammed Amir , Puri, Ajit S , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Ota, Takahiro , Mowla, Ashkan , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Gory, Benjamin , Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Pedicelli, Alessandro , Mendes Pereira, Vitor , Dmytriw, Adam A. , Investigators, the MAD MT

Mayo Clinic

Stroke: Vascular and Interventional Neurology | October 26, 2024 | Volume: 4 | Issue: 6 | Pages: No page available

10.1161/svin.124.001421 | PMID 41583405 Get It

Background Acute ischemic stroke arising from medium vessel occlusions (MeVO) poses substantial challenges in treatment and management. This study aims to elucidate the outcomes and factors contributing to achieving excellent recanalization (modified Thrombolysis in Cerebral Infarction [mTICI] 2c–3) versus successful recanalization (mTICI 2b) in patients with MeVO stroke undergoing mechanical thrombectomy (MT). Methods We conducted a multinational study analyzing data from the MAD‐MT (Multicenter Analysis of Distal Medium Vessel Occlusions: Effect of Mechanical Thrombectomy) registry, encompassing 37 centers across North America, Asia, and Europe, collected between September 2017 and July 2023. The study included acute ischemic stroke patients with MeVO treated with MT, with or without intravenous thrombolysis, who achieved mTICI 2b–3 post‐MT. Results Among 1463 patients with successful recanalization (mTICI 2b–3), 523 achieved mTICI 2b recanalization, and 940 achieved mTICI 2c–3. Distal occlusions exhibited higher odds of excellent recanalization compared with proximal MeVO vessel occlusions (odds ratio, 1.58; 95% CI, 1.17–2.15; P = 0.003). Cardioembolic stroke pathogenesis was associated with a higher likelihood of excellent recanalization (1.67; 95% CI, 1.07–2.59; P = 0.018). Patients achieving mTICI 2c–3 recanalization demonstrated lower initial National Institutes of Health Stroke Scale scores, significant improvements in postprocedural National Institutes of Health Stroke Scale shift, and a higher percentage of favorable 90‐day outcomes compared with those with mTICI 2b. However, no significant difference in 90‐day mortality rates was observed. Conclusion This study underscores that among patients with MeVO stroke with successful recanalization (mTICI 2b–3) there is higher likelihood of achieving excellent recanalization (mTICI 2c–3) in distal occlusions and cardioembolic pathogenesis. mTICI 2c–3 scores post‐MT correlate with improved clinical outcomes compared with mTICI 2b, affirming the superiority of excellent recanalization over successful recanalization in patients with MeVO stroke. Further prospective studies and randomized controlled trials are warranted for validation.
Endovascular therapy versus medical management in isolated posterior cerebral artery acute ischemic stroke: A multinational multicenter propensity score-weighted study
Salim, Hamza , Pulli, Benjamin , Yedavalli, Vivek, Musmar, Basel , Adeeb, Nimer , Lakhani, Dhairya A. , Essibayi, Muhammed Amir , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane , Grewal, Inayat , Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J , Rouchaud, Aymeric, Sheth, Sunil G. , Puri, Ajit S., Dyzmann, Christian , Barreau, Xavier, Filipe, João Pedro , Harker, Pablo, Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent, Gory, Benjamin, Stracke, Christian Paul , Hecker, Constantin, Shaikh, Hamza, Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario, Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien, Investigators, for the MAD MT, Heit, Jeremy J. , Yedavalli, Vivek , Salim, Hamza , Lakhani, Dhairya , Scarcia, Luca , Regenhardt, Robert W , Fiehler, Jens , Alexandru Radu, Răzvan , Klein, Piers , Ota, Takahiro , Jabbour, Pascal , Nguyen, Thanh N , Gonzalez, Nestor R , Möhlenbruch, Markus A , Liebeskind, David S. , Alexandre, Andrea M , Faizy, Tobias D , Wintermark, Max , Heit, Jeremy J , Altschul, David J , Musmar, Basel , Essibayi, Muhammed Amir , Yedavalli, Vivek S , Henninger, Nils , Tan, Benjamin Yq , Pulli, Benjamin , Varela, Ricardo , Naamani, Kareem El , Kühn, Anna Luisa , Ghozy, Sherief , Cancelliere, Nicole M , Bernstock, Joshua D. , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil, Puri, Ajit S , Colasurdo, Marco , Barreau, Xavier , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Mowla, Ashkan , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Costalat, Vincent , Gory, Benjamin , Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Griessenauer, Christoph J. , Pedicelli, Alessandro , Tancredi, Illario , Mendes Pereira, Vitor , Guenego, Adrien , Dmytriw, Adam A. , Investigators, for the MAD MT

Mayo Clinic

European Stroke Journal | October 21, 2024 | Volume: 10 | Issue: 2 | Pages: 387-396

10.1177/23969873241291465 | PMID 39431327 Get It

Abstract Background: Despite the proven effectiveness of endovascular therapy (EVT) in acute ischemic strokes (AIS) involving anterior circulation large vessel occlusions, isolated posterior cerebral artery (PCA) occlusions (iPCAo) remain underexplored in clinical trials. This study investigates the comparative effectiveness and safety of EVT against medical management (MM) in patients with iPCAo. Methods: This multinational, multicenter propensity score-weighted study analyzed data from the Multicenter Analysis of primary Distal medium vessel occlusions: effect of Mechanical Thrombectomy (MAD-MT) registry, involving 37 centers across North America, Asia, and Europe. We included iPCAo patients treated with either EVT or MM. The primary outcome was the modified Rankin Scale (mRS) at 90 days, with secondary outcomes including functional independence, mortality, and safety profiles such as hemorrhagic complications. Results: A total of 177 patients were analyzed (88 MM and 89 EVT). EVT showed a statistically significant improvement in 90-day mRS scores (OR = 0.55, 95% CI = 0.30–1.00, p = 0.048), functional independence (OR = 2.52, 95% CI = 1.02–6.20, p = 0.045), and a reduction in 90-day mortality (OR = 0.12, 95% CI = 0.03–0.54, p = 0.006) compared to MM. Hemorrhagic complications were not significantly different between the groups. Conclusion: EVT for iPCAo is associated with better neurological outcomes and lower mortality compared to MM, without an increased risk of hemorrhagic complications. Nevertheless, these results should be interpreted with caution due to the study’s observational design. The findings are hypothesis-generating and highlight the need for future randomized controlled trials to confirm these observations and establish definitive treatment guidelines for this patient population.
Promise and Peril of a Genotype‐First Approach to Mendelian Cardiovascular Disease
Asatryan, Babken , Murray, Brittney , Tadros, Rafik , Shah, Ravi A. , Dabbagh, Ghaith Sharaf , Landstrom, Andrew P. , Dobner, Stephan , Munroe, Patricia B. , Haggerty, Christopher M. , Owens, Anjali , Semsarian, Christopher , Barth, Andreas S. , Roden, Dan M. , Ware, James S. , Investigators, the Genotype‐First Approach, Shah, Ravi A , Sharaf Dabbagh, Ghaith , Landstrom, Andrew P , Dobner, Stephan , Munroe, Patricia B , Haggerty, Christopher M , Medeiros-Domingo, Argelia , Owens, Anjali T , Kullo, Iftikhar J , Semsarian, Christopher , Reichlin, Tobias , Barth, Andreas S , Roden, Dan M. , James, Cynthia A , Ware, James S , Chahal, Choudhary Anwar A , Asatryan, Babken , Tadros, Rafik , Rieder, Marina , Medeiros‐Domingo, Argelia , Kullo, Iftikhar J. , James, Cynthia A. , Chahal, C. Anwar A. , Investigators, the Genotype‐First Approach

Mayo Clinic

Journal of the American Heart Association | October 18, 2024 | Volume: 13 | Issue: 21 | Pages: No page available

10.1161/jaha.123.033557 | PMID 39424414 Get It

Precision medicine, which among other aspects includes an individual's genomic data in diagnosis and management, has become the standard‐of‐care for Mendelian cardiovascular disease (CVD). However, early identification and management of asymptomatic patients with potentially lethal and manageable Mendelian CVD through screening, which is the promise of precision health, remains an unsolved challenge. The reduced costs of genomic sequencing have enabled the creation of biobanks containing in‐depth genetic and health information, which have facilitated the understanding of genetic variation, penetrance, and expressivity, moving us closer to the genotype‐first screening of asymptomatic individuals for Mendelian CVD. This approach could transform health care by diagnostic refinement and facilitating prevention or therapeutic interventions. Yet, potential benefits must be weighed against the potential risks, which include evolving variant pathogenicity assertion or identification of variants with low disease penetrance; costly, stressful, and inappropriate diagnostic evaluations; negative psychological impact; disqualification for employment or of competitive sports; and denial of insurance. Furthermore, the natural history of Mendelian CVD is often unpredictable, making identification of those who will benefit from preventive measures a priority. Currently, there is insufficient evidence that population‐based genetic screening for Mendelian CVD can reduce adverse outcomes at a reasonable cost to an extent that outweighs the harms of true‐positive and false‐positive results. Besides technical, clinical, and financial burdens, ethical and legal aspects pose unprecedented challenges. This review highlights key developments in the field of genotype‐first approaches to Mendelian CVD and summarizes challenges with potential solutions that can pave the way for implementing this approach for clinical care.
P12.09.A EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA
Hanft, Simon , Elder, B L, Giglio, Pierre , Wu, Siqi , Farrell, Christopher , Alnahhas, Iyad , Lee, I-Y., Walbert, Tobias , Boockvar, John A. , Aregawi, Dawit , Kim, L., Schulder, Michael , Singer, S, Correia, Carlos Eduardo Silva , Ramakrishna, Rohan , Jeyapalan, Suriya, Magge, Rajiv , Agarwal, Vijay , Amankulor, N, Quinones-Hinojosa, A, Neese, Laura L., Scott, Charles , Pérez‐Ollé, Raül, Andrews, David , Lee, Ian , Lee, Ian Y , Elder, B, Lee, I Y, Vojnic, Morana , Zacharia, Brad E. , Kim, L., Ghatan, Saadi , Wu, J, Patel, Nitesh V. , Bhatia, Ankush , Brennan, Cameron , Evans, L, Gill, B, Sengupta, Soma , Wong, Eric T. , Amankulor, N, Quinones-Hinojosa, A, Andrews, D

Mayo Clinic

Neuro-Oncology | October 17, 2024 | Volume: 26 | Issue: Supplement_5 | Pages: v67-v68

10.1093/neuonc/noae144.222 Get It

Abstract BACKGROUND Glioblastoma (GBM) is the most common primary brain malignancy in adults. Standard of care (SOC) for suspected GBM begins with maximal safe resection followed by adjuvant radiotherapy and temozolomide, and maintenance temozolomide. Imvax has utilized its Goldspire™ platform to create IGV-001, an autologous biologic-device combination product for the treatment of newly diagnosed GBM (ndGBM). IGV-001 consists of autologous GBM tumor cells and an antisense oligonucleotide against IGF-1R mRNA (IMV-001), irradiated and administered via biodiffusion chambers implanted in the abdomen. Together, these components stimulate immunogenic cell death and antigen release. In a phase 1b study in patients with ndGBM, IGV-001 was well tolerated without unexpected adverse events. Multiple efficacy signals were also observed, including significant improvements in progression-free survival, overall survival, radiographic evidence of tumor response, and changes in immune response biomarkers. A phase 2b randomized, multicenter, double-blind, placebo-controlled study to assess the safety and efficacy of IGV-001 in patients with ndGBM (ClinicalTrials.gov identifier: NCT04485949) is ongoing. Here, we present the first safety data from the study. MATERIAL AND METHODS After surgical resection, patients are treated with IGV-001 or placebo followed by SOC. The study will enroll approximately 93 patients at 20 sites in the United States, with a 2:1 randomization favoring IGV-001. The primary outcome is progression-free survival, defined as the time from randomization to first progression, as determined by blinded central radiology review, or death. Secondary outcomes include overall survival, defined as the time from randomization to death due to any cause, and safety. RESULTS As of February 2, 2024, a total of 72 patients have been randomized and 69 have been implanted with IGV-001 or placebo plus SOC. The median age was 60.0 years (range, 24-70 years). Most randomized patients (76.4%) were 51-70 years of age, and the male:female ratio was 2.27. A total of 39/45 (86.7%) patients with enough follow-up time, initiated treatment with concurrent radiation and temozolomide. A total of 9/72 (12.5%) randomized patients discontinued treatment, including 7 patients who discontinued during the SOC treatment period. No patients discontinued treatment for adverse events, protocol deviations, or death. A total of 11/72 (15.3%) randomized patients discontinued the study after randomization. CONCLUSION To date, the review of blinded safety data did not show any emerging risk and supports that there is no change to the benefit-risk profile of treatment with IGV-001 versus placebo. The data will be updated before presentation.
Effects of epileptic seizures on the quality of biosignals recorded from wearables
Böttcher, Sebastian , Zabler, Nicolas , Jackson, Michele , Bruno, Elisa , Biondi, Andrea , Epitashvili, Nino , Vieluf, Solveig , Richardson, Mark P. , Brinkmann, Benjamin H. , Dümpelmann, Matthias , Richardson, Mark P , Brinkmann, Benjamin H , Loddenkemper, Tobias , Schulze-Bonhage, Andreas , Biondi, Andrea , Bruno, Elisa , Vieluf, Solveig , Dümpelmann, Matthias , Loddenkemper, Tobias , Schulze‐Bonhage, Andreas

Mayo Clinic

Epilepsia | October 7, 2024 | Volume: 65 | Issue: 12 | Pages: 3513-3525

10.1111/epi.18138 | PMID 39373185 Get It

Abstract Objective Wearable nonelectroencephalographic biosignal recordings captured from the wrist offer enormous potential for seizure monitoring. However, signal quality remains a challenging factor affecting data reliability. Models trained for seizure detection depend on the quality of recordings in peri‐ictal periods in performing a feature‐based separation of ictal periods from interictal periods. Thus, this study aims to investigate the effect of epileptic seizures on signal quality, ensuring accurate and reliable monitoring. Methods This study assesses the signal quality of wearable data during peri‐ictal phases of generalized tonic–clonic and focal to bilateral tonic–clonic seizures (TCS), focal motor seizures (FMS), and focal nonmotor seizures (FNMS). We evaluated accelerometer (ACC) activity and the signal quality of electrodermal activity (EDA) and blood volume pulse (BVP) data. Additionally, we analyzed the influence of peri‐ictal movements as assessed by ACC (ACC activity) on signal quality and examined intraictal subphases of focal to bilateral TCS. Results We analyzed 386 seizures from 111 individuals in three international epilepsy monitoring units. BVP signal quality and ACC activity levels differed between all seizure types. We found the largest decrease in BVP signal quality and increase in ACC activity when comparing the ictal phase to the pre‐ and postictal phases for TCS. Additionally, ACC activity was strongly negatively correlated with BVP signal quality for TCS and FMS, and weakly for FNMS. Intraictal analysis revealed that tonic and clonic subphases have the lowest BVP signal quality and the highest ACC activity. Significance Motor elements of seizures significantly impair BVP signal quality, but do not have significant effect on EDA signal quality, as assessed by wrist‐worn wearables. The results underscore the importance of signal quality assessment methods and careful selection of robust modalities to ensure reliable seizure detection. Future research is needed to explain whether seizure detection models' decisions are based on signal responses induced by physiological processes as opposed to artifacts.
Mensch-Maschine-Interaktion: Einfluss künstlicher Intelligenz auf das diagnostische Vertrauen von Endoskopikern bei der Beurteilung des Barrett-Ösophagus
Röser, D, Meinikheim, M. , Mendel, Rosmarie, Palm, Christian, Rauber, David , Rückert, Tobias, Parsa, Nasim , Ebigbo, Alanna , Roser, D., Mendel, R., Muzalyova, Anna , Byrne, M., Messmann, Helmut

Mayo Clinic

Zeitschrift für Gastroenterologie | October 2, 2024 | Volume: 62 | Issue: 09 | Pages: e575-e576

10.1055/s-0044-1789656 Get It

Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite Anticoagulation
Seiffge, David , Group, STR-OAC LAAO, Macha, Kosmas , Takagi, Masahito, Arihiro, Shoji , Polymeris, Alexandros A. , Yoshimura, Sohei , Venti, Michele , Thilemann, Sebastian , Altavilla, Riccardo , Peters, Nils , Inoue, Manabu, Bobinger, Tobias , Agnelli, Giancarlo , Acciarresi, Monica, Jager, Hans, Bovi, Paolo, Schwab, Stefan , Registry, RAF, RAF-DOAC, CROMIS-2, SAMURAI, NOACISP, Erlangen Registry, and Verona, Aarnink, Errol W. , Fierro, Nicolai, Tondo, Claudio , Zieliński, Kamil , Korsholm, Kasper , Nielsen-Kudsk, Jens Erik, Caneiro‐Queija, Berenice, Benito‐González, Tomás , Holmes, David R. , Almakadma, Abdul H., Álvarez, Xavier Millán, Alla, Venkata , Agarwal, Himanshu , Paitazoglou, Christina , Freixa, Xavier , Cepas‐Guillén, Pedro , Chothia, Rashaad , Badejoko, Solomon O. , Bergmann, Martin , Spoon, Daniel B., Maddux, James T., Ram, Pradhum , Branca, Luca , Dijk, Vincent F. van , Rensing, Benno J. , Paciaroni, Maurizio , Kallmünzer, Bernd , Wilson, Duncan , Jäger, Hans Rolf , Korsholm, Kasper , Seiffge, David , Jäger, Hans Rolf , Cepas-Guillen, Pedro , Maarse, Moniek , Werring, David J. , Boersma, Lucas V.A. , Group, STR-OAC LAAO, Tsivgoulis, Georgios , Bonetti, Bruno , Alberti, Andrea , Ambler, Gareth , Bonati, Leo H. , Muir, Keith W. , Yamagami, Hiroshi, Inoue, Manabu , Brown, Martin M. , Sato, Shoichiro , Lyrer, Philippe A. , Marchis, Gian Marco De , Peper, Joyce , Simard, Trevor , Alkhouli, Mohamad , Registry, RAF, RAF-DOAC, CROMIS-2, SAMURAI, NOACISP, Erlangen Registry, and Verona, Mazzone, Patrizio , Beneduce, Alessandro , Gasperetti, Alessio , Pracoń, Radosław , Demkow, Marcin , Backer, Ole De , Nielsen‐Kudsk, Jens Erik , Estévez‐Loureiro, Rodrigo , Prado, Armando Pérez de , Nombela‐Franco, Luis , Salinas, Pablo , Berti, Sérgio , Romeo, Maria Rita , Arzamendi, Dabit , Eitel, Ingo , Bergmann, Martin W., El‐Chami, Mikhael F. , Adamo, Marianna , Suradi, Hussam , Zietz, Annaelle , Caso, Valeria , Koga, Masatoshi , Toyoda, Ḱazunori , Cappellari, Manuel , Engelter, Stefan T. , Swaans, Martin John

Mayo Clinic

JAMA Neurology | September 23, 2024 | Volume: 81 | Issue: 11 | Pages: 1150

10.1001/jamaneurol.2024.2882 | PMID 39374446 Get It

ImportancePatients with atrial fibrillation (AF) who have ischemic stroke despite taking oral anticoagulation therapy (OAT) have a very high risk of recurrence. Left atrial appendage occlusion (LAAO) is a mechanical stroke prevention strategy that may provide additional protection in patients with thromboembolic events under OAT.ObjectiveTo compare percutaneous LAAO with continuing OAT alone regarding stroke prevention in patients with AF who had a thromboembolic event despite taking OAT.Design, Setting, and ParticipantsThis cohort study was a propensity score–matched comparison of the STR-OAC LAAO cohort, an international collaboration of 21 sites combining patients from multiple prospective registries of patients who underwent LAAO between 2010 and 2022. STR-OAC LAAO cohort patients who had follow-up longer than 3 months were propensity score–matched to a previously published control cohort comprising patients from an established international collaboration of investigator-initiated prospective studies. This control cohort included patients with nonvalvular AF, recent ischemic stroke or transient ischemic attack, and follow-up longer than 3 months who were taking OAT before the index event. Analyses were adjusted for imbalances in gender, age, hypertension, diabetes, and CHA2 DS2-VASc score.ExposureLeft atrial appendage occlusion vs continuation of oral anticoagulation therapy alone (control group).Main Outcomes and MeasuresThe primary outcome was time to first ischemic stroke.ResultsFour hundred thirty-three patients from the STR-OAC LAAO cohort (mean [SD] age, 72 [9] years; 171 [39%] females and 262 [61%] males; mean [SD] CHA2 DS2-VASc score, 5.0 [1.6]) were matched to 433 of 1140 patients (38%) from the control group. During 2-year follow-up, 50 patients experienced ischemic stroke: an annualized event rate of 2.8% per patient-year in the STR-OAC LAAO group vs 8.9% per patient-year in the control group. Left atrial appendage occlusion was associated with a lower risk of ischemic stroke (hazard ratio, 0.33; 95% CI, 0.19-0.58; P < .001) compared with the control group. After LAAO, OAT was discontinued in 290 patients (67%), and the remaining 143 patients (33%) continued OAT after LAAO as an adjunctive therapy.Conclusions and RelevanceIn patients with nonvalvular AF and a prior thromboembolic event despite taking OAT, LAAO was associated with a lower risk of ischemic stroke compared with continued OAT alone. Randomized clinical trial data are needed to confirm that LAAO may be a promising treatment option for this population with a very high risk of stroke.
Outcomes related to penile prosthesis reservoir removal: a 7-year multi-institutional experience
Piraino, Javier , Madison, Ian, Supak, Dylan N., Trost, Landon , Cornell, Robert J., Köhler, Tobias , Henry, Gerard D., Loeb, Aram, Wang, Run , Hernandez, J. Clavell, Piraino, Javier

Mayo Clinic

The Journal of Sexual Medicine | September 14, 2024 | Volume: 21 | Issue: 11 | Pages: 1076-1080

10.1093/jsxmed/qdae112 | PMID 39271240 Get It

Abstract Background The 3-piece inflatable penile prosthesis (IPP) is the most widely used device for erectile dysfunction refractory to medications, containing a reservoir inserted into the retropubic space (RPS) or an alternative/ectopic space (AES). Indications for removal of the reservoir include malfunction, malposition, or infection. In revision cases without infection, reservoir removal is sometimes optional. Aim We reviewed outcomes and complications related to reservoir removal from a large multi-institutional series. Methods We retrospectively reviewed databases at 6 institutions over 7 years. Patients with artificial urethral sphincter, urethral sling, or mini-jupette were excluded. Outcomes Outcomes and complications related to IPP reservoir removal were analyzed. Data were collected, but only reservoir-related complications at surgery were included. Data were compared between the RPS and AES cohorts to evaluate differences with a χ2 test, with significance at P < .05. Results Of 215 cases, there were 172 RPS and 43 AES reservoirs. The mean patient age was 65.3 years. An overall 131 procedures were due to malfunction and 49 to malposition of an IPP component; 35 were secondary to infection. Among those retained (n = 44), reasons included reuse, avoiding surrounding structure damage, and difficult dissection. Among those removed (n = 171), 15 required a counterincision. To determine the statistical difference between those removed from the RPS and an AES, the χ2 test result was P = .00059, indicating a significant difference in the need for a counterincision between the groups. Complications included bladder perforation (n = 1) in the RPS group and an avulsion of the epigastric vessels requiring abdominal exploration (n = 1) in the AES group. To determine the statistical difference between RPS and AES complications, the χ2 test result was P = .365, indicating no significant difference between the groups. Strengths and Limitations Strengths include being a multi-institutional study with high-volume skilled implanters. Limitations include being a retrospective review, with implanters exclusively performing penoscrotal incisions and not utilizing an infrapubic approach. Last, there was a lack of long-term follow-up with these patients. Conclusions Removal of an IPP reservoir remains safe, with few intraoperative complications. Surgeons should be aware of the inferior epigastric vessels during removal in an AES or be willing to perform a counterincision to avoid injury to surrounding structures. Surgeons should also obtain preoperative imaging to identify the specific location of the reservoir and adjacent anatomy. This is the first multi-institutional study reviewing outcomes related to reservoir removal during IPP revision or removal surgery.
Predictive value of follow-up infarct volume on functional outcomes in middle cerebral artery M2 segment vessel occlusion stroke treated with mechanical thrombectomy
Yedavalli, Vivek, Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Kühn, Anna Luisa, Khalife, Jane, Ghozy, Sherief, Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J , Rouchaud, Aymeric, Sheth, Sunil, Puri, Ajit S., Dyzmann, Christian , Colasurdo, Marco, Barreau, Xavier, Renieri, Leonardo, Filipe, João Pedro , Harker, Pablo, Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Essibayi, Muhammed Amir , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent, Gory, Benjamin, Stracke, Christian Paul , Hecker, Constantin, Shaikh, Hamza, Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario, Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien, Investigators, for the MAD MT, Heit, Jeremy J. , Yedavalli, Vivek , Colasurdo, Marco , Salim, Hamza , Scarcia, Luca , Regenhardt, Robert W , Fiehler, Jens , Alexandru Radu, Răzvan , Klein, Piers , Ota, Takahiro , Jabbour, Pascal , Nguyen, Thanh N , Essibayi, Muhammed Amir , Gonzalez, Nestor R , Möhlenbruch, Markus A , Liebeskind, David S. , Alexandre, Andrea M , Heit, Jeremy J , Altschul, David J , Musmar, Basel , Yedavalli, Vivek S , Colasurdo, Marco , Henninger, Nils , Tan, Benjamin Yq , Varela, Ricardo , Naamani, Kareem El , Kühn, Anna Luisa , Khalife, Jane , Ghozy, Sherief , Cancelliere, Nicole M , Bernstock, Joshua D. , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil A , Puri, Ajit S , Barreau, Xavier , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Mowla, Ashkan , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Costalat, Vincent , Gory, Benjamin , Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Pedicelli, Alessandro , Tancredi, Illario , Mendes Pereira, Vitor , Guenego, Adrien , Dmytriw, Adam A. , Investigators, for the MAD MT

Mayo Clinic

European Stroke Journal | September 14, 2024 | Volume: 10 | Issue: 2 | Pages: 431-441

10.1177/23969873241275531 | PMID 39269154 Get It

Abstract Background: Medium vessel occlusion (MeVO) strokes, particularly affecting the M2 segment of the middle cerebral artery, represent a critical proportion of acute ischemic strokes, posing significant challenges in management and outcome prediction. The efficacy of mechanical thrombectomy (MT) in MeVO stroke may warrant reliable predictors of functional outcomes. This study aimed to investigate the prognostic value of follow-up infarct volume (FIV) for predicting 90-day functional outcomes in MeVO stroke patients undergoing MT. Methods: This multicenter, retrospective cohort study analyzed data from the Multicenter Analysis of primary Distal medium vessel occlusions: effect of Mechanical Thrombectomy (MAD-MT) registry, covering patients with acute ischemic stroke due to M2 segment occlusion treated with MT. We examined the relationship between 90-day functional outcomes, measured by the modified Rankin Scale (mRS), and follow-up infarct volume (FIV), assessed through CT or MRI within 12–36 h post-MT. Results: Among 130 participants, specific FIV thresholds were identified with high specificity and sensitivity for predicting outcomes. A FIV ⩽5 ml was highly specific for predicting favorable and excellent outcomes. The optimal cut-off for both prognostications was identified at ⩽15 ml by the Youden Index, with significant reductions in the likelihood of favorable outcomes observed above a 40 ml threshold. Receiver Operator Curve (ROC) analyses confirmed FIV as a superior predictor of functional outcomes compared to traditional recanalization scores, such as final modified thrombolysis in cerebral infarction score (mTICI). Multivariable analysis further highlighted the inverse relationship between FIV and positive functional outcomes. Conclusions: FIV within 36 h post-MT serves as a potent predictor of 90-day functional outcomes in patients with M2 segment MeVO strokes. Establishing FIV thresholds may aid in the prognostication of stroke outcomes, suggesting a role for FIV in guiding post intervention treatment decisions and informing clinical practice. Future research should focus on validating these findings across diverse patient populations and exploring the integration of FIV measurements with other clinical and imaging markers to enhance outcome prediction accuracy.
Lessons learned from the Sexual Medicine Society of North America fellowship bootcamp
Köhler, Tobias S. , Hashemi, Milad Bonakdar , Morey, Allen F. , Nelson, Christian J. , Trost, Landon , Ziegelmann, Matthew , Khera, Mohit , Bonakdar Hashemi, Milad, Helo, Sevann , Nelson, Christian J , Ziegelmann, Matthew J

Mayo Clinic

The Journal of Sexual Medicine | August 26, 2024 | Volume: 21 | Issue: 10 | Pages: 961-966

10.1093/jsxmed/qdae099 | PMID 39186946 Get It

Abstract Background Sexual Medicine Society of North America (SMSNA) fellowships offer variable experience in sexual health domains: erectile dysfunction, Peyronie’s disease, male infertility, male hypogonadism (low testosterone), reconstruction (including male incontinence), benign prostatic hyperplasia, gender affirmation surgery, sexual mental health, and female sexual dysfunction. Aim To evaluate baseline and postbootcamp understanding and trust in these domains. Methods In 2023, 28 of 31 urologists currently enrolled in SMSNA-endorsed fellowships participated in a 3.5-day training bootcamp in Minneapolis, Minnesota. Participants were asked to complete pre- and postbootcamp surveys. The bootcamp curriculum offered American Urological Association guidelines and case-based lectures, hands-on clinical training with cadavers (penile surgery) and models (collagenase training), and interaction with industry. Outcomes Changes in knowledge, independence, and trust in performing the procedures, as well as billing issues and feedback for future bootcamps. Results Prebootcamp surveys revealed vastly varied residency experience. Reported time with an expert faculty member was greatest for benign prostatic hyperplasia and least for female sexual dysfunction, gender affirmation surgery, and low testosterone. The lowest prebootcamp confidence in performing surgery independently was for penile grafting procedures and elevating the neurovascular bundle. Postbootcamp results revealed several areas of significant improvement in confidence (P ≤ .03): intralesional injections for Peyronie’s disease, manual modeling, penile plication, penile grafting procedures, and elevating the neurovascular bundle. There was a trend for improved confidence with the insertion of inflatable (P = .05) and semirigid (P = .08) penile prostheses. Nonsignificant improvement occurred in artificial urinary sphincter surgery (P = .12). Participants graded the bootcamp very highly and requested that next year’s bootcamp have more content on female sexual dysfunction, male incontinence, and low testosterone, as well as more hands-on skills sessions and case-based lecture formats. Clinical Implications Offering a bootcamp with hands-on instruction could significantly improve urologists’ knowledge and confidence. Strengths and Limitations As the main strength, this study was the first specialized bootcamp for urologists in the subject of men’s health, taking into account hands-on and cadaver laboratories, as well as highlighting industrial and pharmaceutical products. The small sample size was the major limitation. Conclusions Current SMSNA fellows present with varied levels of experience and confidence across sexual health domains. Notable confidence improvements were seen with topics that combined didactic lectures with hands-on trainings.